“The ACE2 enzyme is the entry receptor for the SARS-CoV-2 virus. The spike of the virus binds to ACE2 on the surface of the cell which is a crucial step to the cell being infected,” said Professor Phil Hansbro, Director of the Centenary UTS Centre for Inflammation and co-author on the study.
“We found increased ACE2 expression occurring in older people and males which may explain their higher risk profiles for COVID-19,” he said.
“We also discovered lower ACE2 levels in people with asthma which may indicate why this population group appear to suffer less from severe coronavirus complications.”
The study was led by Professor Peter Wark from the Hunter Medical Research Institute and the University of Newcastle and was published in the journal ‘Respirology’.